Zoetis hikes dividend under shareholder pressure; Investors sue Valeant, Ackman for insider trading;

@FiercePharma: Have you read our latest report? Not to be missed: The top 10 patent losses of 2015. Report | Follow @FiercePharma

@CarlyHFierce: ICYME: Flush-with-cash Shire revisits deal for NPS Pharma. More | Follow @CarlyHFierce

> Animal health leader Zoetis ($ZTS), under pressure to improve shareholder value since activist investor Bill Ackman bought up a $1.5 billion stake, says its first-quarter 2015 dividend will be 8.3 cents per share--15% higher than this year's dividend rate. Story

> Investors who sold shares of Allergan ($AGN) between February and April are suing Bill Ackman and Valeant ($VRX) for insider trading. More

> The FDA has cleared Teva's ($TEVA) allergy drug QNASL in children age 4 to 11. Release

> Sanofi ($SNY) has leased 40,000 square feet of office space in Miami, FL. Report

> The EU has recommended approval of Italian drugmaker Chiesi's rare eye disease drug Holoclar, the first medicine containing stem cells. Story

> Novartis ($NVS) had won approval in India to import and market its Cushing's disease drug Pasireotide without having to do local clinical trials. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. Article | Follow @FierceMedDev

@EmilyWFierce: Myriad Genetics stymied in BRCA breast cancer test patent battle. Story | Follow @EmilyWFierce

> Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. More

> Small cap Cerus spikes on back-to-back Intercept approvals by FDA. News

> FDA outlines UDI implementation plans for 2015. More

Biotech News

@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech

@JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists and shout 'amyloid beta.' | Follow @JohnCFierce

@DamianFierce: $MRK + $CBST tick-tock shows Frazier wanted $HSP decision contingency and Bonney talked him out of it. More | Follow @DamianFierce

> Gilead buys into Ono's cancer drug as it scales up in oncology. News

> Lilly makes amends with Adocia in $570M diabetes deal. Story

> Roche scuttles PhIII Alzheimer's study in yet another setback for the field. More

And Finally... According to a new investigation, hundreds of thousands of Americans are falling prey to pharma spam and buying drugs from rogue pharmacy websites. Report

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.